Discover trends, market shifts, and competitive outlooks for the intermittent claudication industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Estimated Market Size of the Intermittent Claudication Market In 2029?

In the past few years, the market size for intermittent claudication has seen a robust growth. It is projected to expand from $12.81 billion in 2024 to $13.64 billion in 2025, at a compound annual growth rate (CAGR) of 6.5%. The historical growth of this market can be credited to the surging cases of peripheral artery disease, increased consciousness about vascular diseases, a burgeoning aging population, a rise in diagnostic rates, and a growth in healthcare spending.

There’s a forecast of robust expansion in the intermittent claudication market in the forthcoming years. The market is projected to scale up to $17.39 billion by 2029, with a compound annual growth rate (CAGR) of 6.2%. Factors propelling growth during the forecast period include increased diabetes cases, escalating obesity rates, a surge in cardiovascular diseases, a rise in alcohol and tobacco use, and augmented healthcare expenditure. The forecast period will also see key trends such as improvement in pad diagnostics, the incorporation of wearable tech, the inclusion of personalized medicine, a move towards drug-eluting stents, and progress in stem cell therapy.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22021&type=smp

Which Primay Drivers Are Accelerating Growth in the Intermittent Claudication Market?

The escalation in peripheral artery disease (PAD) instances is set to stimulate the advancement of the intermittent claudication market in the future. PAD is essentially a circulatory issue wherein arteries get constricted, leading to a decreased blood flow to the limbs, resulting in pain, numbness, and other complications. The rise in PAD is linked to aspects such as an aging populace, diabetes, smoking, hypertension, obesity, and inactive lifestyles. PAD induces intermittent claudication by curtailing blood flow to the leg muscles while exercising, thereby causing pain and cramping due to lack of oxygen. For example, the American Heart Association Journals, a peer-reviewed open-access scientific journal based in the U.S., reported in June 2023, that PAD impacts 7-12 million people in the U.S. and 200 million people worldwide. Consequently, the escalating instances of peripheral artery disease (PAD) are propelling the growth of the intermittent claudication market.

Which Primary Segments of the Intermittent Claudication Market Are Driving Growth and Industry Transformations?

The intermittent claudication market covered in this report is segmented –

1) By Type: Medication Therapies, Revascularization

2) By Route Of Administration: Parenteral Route, Oral Route, Other Routes Of Administration

3) By Application: Hospitals, Clinics, Home Healthcare, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Medication Therapies: Antiplatelet Agents, Vasodilators, Phosphodiesterase Inhibitors, Cilostazol, Pentoxifylline

2) By Revascularization: Angioplasty, Stenting, Bypass Surgery, Endarterectomy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22021&type=smp

Which Regions Are Key Players in the Growth of the Intermittent Claudication Market?

North America was the largest region in the intermittent claudication market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intermittent claudication market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Intermittent Claudication Industry Dynamics?

In an attempt to improve the treatment results for patients with intermittent claudication, a symptom of peripheral artery disease (PAD), major firms in the market are dedicating resources to the development of advanced medication therapies. These companies are particularly interested in RIPK1 inhibitors, innovative drugs that have the potential to enhance blood flow, reduce inflammation, and prevent the progression of PAD. These inhibitors function by blocking RIPK1 kinase activity, thus reducing inflammation and cellular death. For example, GenFleet, a Chinese biotechnology corporation, was granted approval for a Phase II clinical trial of their novel therapy, GFH312, by the US Food and Drug Administration (FDA) in August 2022. The trial, a randomized, double-blinded, placebo-controlled study, will take place across 15 research centers. GFH312 is a RIPK1 inhibitor that has demonstrated promising results in preclinical studies, specifically in reducing the inflammatory response in animal models.

View the full report here:

https://www.thebusinessresearchcompany.com/report/intermittent-claudication-global-market-report

What Parameters Are Used to Define the Intermittent Claudication Market?

Intermittent claudication is a condition characterized by muscle pain, cramping, or discomfort in the legs that occurs during physical activity, such as walking, and is relieved by rest. It is typically caused by peripheral artery disease (PAD), which results from narrowed or blocked arteries reducing blood flow to the muscles. The pain is often due to insufficient oxygen supply (ischemia) to the affected muscles.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22021

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model